| HRA003285
(Controlled Access)
|
Genetic subtypes of diffuse large B-cell lymphoma (DLBCL) have variable oncogenic alterations and clinical outcomes. We conducted a randomized, phase 2 GUIDANCE-01 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) alone, or with targeted agents guided by genetic subtypes (R-CHOP-X, MCD-like and BN2-like with ibrutinib, N1-like and NOS with lenalidomide, EZB-like with tucidinostat, and TP53mut with decitabine) in newly diagnosed, intermediate-risk or high-risk DLBCL. |
